Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders)
  4. Volume 25, Issue 3
  5. Article
Volume 25, Issue 3
  • ISSN: 1871-5303
  • E-ISSN: 2212-3873

Abstract

Objective

The study aimed to investigate the efficacy and safety of semaglutide in weight loss in non-diabetic people.

Methods

In this study, 84 non-diabetic people who used semaglutide to lose weight in the outpatient department of our hospital from January 1, 2022, to June 30, 2022, were enrolled and compared for changes in body weight, waist circumference, Body Mass Index (BMI), fasting blood glucose, blood pressure, pulse, and body composition (body fat ratio, visceral fat area, and skeletal muscle) before treatment and 12 weeks after the treatment to analyze the weight loss efficacy and safety.

Results

After administering semaglutide 0.25 mg, 0.5 mg, 0.75 mg, or 1.0 mg subcutaneously once a week for 12 weeks, 84 participants in this study obtained an average weight loss of 5.91 ± 3.37 kg, equivalent to 6.15 ± 4.28% of baseline body weight, and there was also a significant reduction in visceral fat area and a slight reduction in blood pressure. The most common adverse reactions included gastrointestinal reactions (nausea, vomiting, and diarrhea), which were mild and subsided within 1-2 days. No severe adverse reaction, such as hypoglycemia and hypotension, was observed.

Conclusion

Low-dose semaglutide has been found to be effective and safe for short-term weight loss in non-diabetic people.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/emiddt/10.2174/0118715303283400240521120048
2024-05-28
2025-01-29

  • From This Site

    /content/journals/emiddt/10.2174/0118715303283400240521120048
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Obesity and overweight. 2021. Available from: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
  2. Report on nutrition and chronic diseases in China (2020).Ying Yang Xue Bao20204206521
     [Google Scholar]
  3. GuhD.P. ZhangW. BansbackN. AmarsiZ. BirminghamC.L. AnisA.H. The incidence of co-morbidities related to obesity and overweight: A systematic review and meta-analysis.BMC Public Health2009918810.1186/1471‑2458‑9‑88 19320986
     [Google Scholar]
  4. GroverS.A. KaouacheM. RempelP. JosephL. DawesM. LauD.C.W. LowensteynI. Years of life lost and healthy life-years lost from diabetes and cardiovascular disease in overweight and obese people: A modelling study.Lancet Diabetes Endocrinol.20153211412210.1016/S2213‑8587(14)70229‑3 25483220
     [Google Scholar]
  5. AfshinA. Health effects of overweight and obesity in 195 countries over 25 years.N. Engl. J. Med.20173771132710.1056/NEJMoa1614362
     [Google Scholar]
  6. MüllerT.D. BlüherM. TschöpM.H. DiMarchiR.D. Anti-obesity drug discovery: Advances and challenges.Nat. Rev. Drug Discov.202221320122310.1038/s41573‑021‑00337‑8 34815532
     [Google Scholar]
  7. WhartonS. LauD.C.W. VallisM. SharmaA.M. BierthoL. Campbell-SchererD. AdamoK. AlbergaA. BellR. BouléN. BoylingE. BrownJ. CalamB. ClarkeC. CrowshoeL. DivalentinoD. ForhanM. FreedhoffY. GagnerM. GlazerS. GrandC. GreenM. HahnM. HawaR. HendersonR. HongD. HungP. JanssenI. JacklinK. Johnson-StoklossaC. KempA. KirkS. KukJ. LangloisM.F. LearS. McInnesA. MacklinD. NajiL. ManjooP. MorinM.P. NerenbergK. PattonI. PedersenS. PereiraL. Piccinini-VallisH. PoddarM. PoirierP. Prud’hommeD. SalasX.R. Rueda-ClausenC. Russell-MayhewS. ShiauJ. SherifaliD. SievenpiperJ. SockalingamS. TaylorV. TothE. TwellsL. TytusR. WaljiS. WalkerL. WicklumS. Obesity in adults: A clinical practice guideline.CMAJ202019231E875E89110.1503/cmaj.191707 32753461
     [Google Scholar]
  8. AhrénB. MasmiquelL. KumarH. SarginM. KarsbølJ.D. JacobsenS.H. ChowF. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): A 56-week, double-blind, phase 3a, randomised trial.Lancet Diabetes Endocrinol.20175534135410.1016/S2213‑8587(17)30092‑X 28385659
     [Google Scholar]
  9. AhmannA.J. CapehornM. CharpentierG. DottaF. HenkelE. LingvayI. HolstA.G. AnnettM.P. ArodaV.R. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): A 56-week, open-label, randomized clinical trial.Diabetes Care201841225826610.2337/dc17‑0417 29246950
     [Google Scholar]
  10. O’NeilP.M. BirkenfeldA.L. McGowanB. MosenzonO. PedersenS.D. WhartonS. CarsonC.G. JepsenC.H. KabischM. WildingJ.P.H. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: A randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial.Lancet20183921014863764910.1016/S0140‑6736(18)31773‑2 30122305
     [Google Scholar]
  11. WildingJ.P.H. BatterhamR.L. CalannaS. DaviesM. Van GaalL.F. LingvayI. McGowanB.M. RosenstockJ. TranM.T.D. WaddenT.A. WhartonS. YokoteK. ZeuthenN. KushnerR.F. Once-weekly semaglutide in adults with overweight or obesity.N. Engl. J. Med.202138411989100210.1056/NEJMoa2032183 33567185
     [Google Scholar]
  12. DaviesM. FærchL. JeppesenO.K. PaksereshtA. PedersenS.D. PerreaultL. RosenstockJ. ShimomuraI. ViljoenA. WaddenT.A. LingvayI. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): A randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.Lancet20213971027897198410.1016/S0140‑6736(21)00213‑0 33667417
     [Google Scholar]
  13. WaddenT.A. BaileyT.S. BillingsL.K. DaviesM. FriasJ.P. KorolevaA. LingvayI. O’NeilP.M. RubinoD.M. SkovgaardD. WallensteinS.O.R. GarveyW.T. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity.JAMA2021325141403141310.1001/jama.2021.1831 33625476
     [Google Scholar]
  14. RubinoD. AbrahamssonN. DaviesM. HesseD. GreenwayF.L. JensenC. LingvayI. MosenzonO. RosenstockJ. RubioM.A. RudofskyG. TadayonS. WaddenT.A. DickerD. FribergM. SjödinA. DickerD. SegalG. MosenzonO. SabbahM. SoferY. VishlitzkyV. MeestersE.W. SerlieM. van BonA. CardosoH. FreitasP. Carneiro de MeloP. MonteiroM. MonteiroM. RodriguesD. BadatA. JoshiP. LatiffG. MithaE.A. SnymanH.H. van NieuwenhuizenE. González AlbarránO. CaixasA. de al CuestaC. Garcia LunaP.P. Morales PortilloC. Mezquita RayaP. RubioM.A. AbrahamssonN. HoffstedtJ. von WowernF. UddmanE. Bach-KliegelB. BeuschleinF. BilzS. GolayA. RudofskyG. StreyC. FadieienkoG. KoseiN. TatarchukT. VelychkoV. ZinychO. AronoffS.L. BaysH.E. BrockmyreA.P. CallR.S. CrumpC. DesouzaC.V. EspinosaV. FreeA.L. GandyW.H. GellerS.A. GottschlichG.M. GreenwayF.L. Han-ConradL. HarperW. HermanL. HewittM. HollanderP. KasterS.R. ManessisA. MartinF.A. McNeillR.E. MurrayA.V. NorwoodP.C. ReedJ.C.H. RosenstockJ. RubinoD.M. SchearM.J. WarrenM.L. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity.JAMA2021325141414142510.1001/jama.2021.3224 33755728
     [Google Scholar]
  15. KadowakiT. IsendahlJ. KhalidU. LeeS.Y. NishidaT. OgawaW. TobeK. YamauchiT. LimS. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): A randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial.Lancet Diabetes Endocrinol.202210319320610.1016/S2213‑8587(22)00008‑0 35131037
     [Google Scholar]
  16. RubinoD.M. GreenwayF.L. KhalidU. O’NeilP.M. RosenstockJ. SørrigR. WaddenT.A. WizertA. GarveyW.T. Arauz-PachecoC. CannonK. DowneyH.J. Fitz-PatrickD. GeohasJ. GeretyG. GilbertJ. HollanderP. KleinE. LauferK. O’DonnellP. RosenblitP. TothP. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes.JAMA2022327213815010.1001/jama.2021.23619 35015037
     [Google Scholar]
  17. KnudsenL.B. LauJ. The discovery and development of liraglutide and semaglutide.Front. Endocrinol.20191015510.3389/fendo.2019.00155 31031702
     [Google Scholar]
  18. BlundellJ. FinlaysonG. AxelsenM. FlintA. GibbonsC. KvistT. HjerpstedJ.B. Effects of once‐weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity.Diabetes Obes. Metab.20171991242125110.1111/dom.12932 28266779
     [Google Scholar]
  19. HolstJ.J. Incretin hormones and the satiation signal.Int. J. Obes.20133791161116810.1038/ijo.2012.208 23295502
     [Google Scholar]
  20. GaberyS. SalinasC.G. PaulsenS.J. Ahnfelt-RønneJ. AlanentaloT. BaqueroA.F. BuckleyS.T. FarkasE. FeketeC. FrederiksenK.S. HelmsH.C.C. JeppesenJ.F. JohnL.M. PykeC. NøhrJ. LuT.T. Polex-WolfJ. PrevotV. RaunK. SimonsenL. SunG. Szilvásy-SzabóA. WillenbrockH. SecherA. KnudsenL.B. HogendorfW.F.J. Semaglutide lowers body weight in rodents via distributed neural pathways.JCI Insight202056e13342910.1172/jci.insight.133429 32213703
     [Google Scholar]
  21. FriedrichsenM. BreitschaftA. TadayonS. WizertA. SkovgaardD. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity.Diabetes Obes. Metab.202123375476210.1111/dom.14280 33269530
     [Google Scholar]
  22. Food and drug administration. FDA guidance for industry: Developing products for weight management. 2007. Available from: https://www.fda.gov/media/71252/download Accessed October 25.
  23. European medicines agency. EMA/CHMP/311805/2014 Guideline on clinical evaluation of medicinal products used in weight management. 2016. Available from: https://www.ema.europa.eu/en/documents/scientific‐guideline/guideline‐clinical‐evaluation‐medicinal‐products‐used‐weight‐management‐revision‐1_en.pdf Accessed October 25.
  24. Food and drug administration. Ozempic (semaglutide) injection, for subcutaneous use. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209637s003lbl.pdf Accessed September 25.
  25. Guidelines for prevention and control of overweight and obesity in chinese adults (Excerpt).Ying Yang Xue Bao20040114
     [Google Scholar]
  26. DombrowskiS.U. KnittleK. AvenellA. Araújo-SoaresV. SniehottaF.F. Long term maintenance of weight loss with nonsurgical interventions in obese adults: Systematic review and metaanalyses of randomised controlled trials.BMJ2014348may146g2646.10.1136/bmj.g264625134100
     [Google Scholar]
  27. GhusnW. De la RosaA. SacotoD. CifuentesL. CamposA. FerisF. HurtadoM.D. AcostaA. Weight loss outcomes associated with semaglutide treatment for patients with overweight or obesity.JAMA Netw. Open202259e223198210.1001/jamanetworkopen.2022.31982 36121652
     [Google Scholar]
  28. ZhongP. ZengH. HuangM. FuW. ChenZ. Efficacy and safety of once-weekly semaglutide in adults with overweight or obesity: A meta-analysis.Endocrine202275371872410.1007/s12020‑021‑02945‑1 34981419
     [Google Scholar]
  29. MarsoS.P. BainS.C. ConsoliA. EliaschewitzF.G. JódarE. LeiterL.A. LingvayI. RosenstockJ. SeufertJ. WarrenM.L. WooV. HansenO. HolstA.G. PetterssonJ. VilsbøllT. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes.N. Engl. J. Med.2016375191834184410.1056/NEJMoa1607141 27633186
     [Google Scholar]
  30. ErlingerS. Gallstones in obesity and weight loss.Eur. J. Gastroenterol. Hepatol.200012121347135210.1097/00042737‑200012120‑00015 11192327
     [Google Scholar]
  31. NreuB. DicembriniI. TintiF. MannucciE. MonamiM. Cholelithiasis in patients treated with glucagon-like peptide-1 receptor: An updated meta-analysis of randomized controlled trials.Diabetes Res. Clin. Pract.202016110808710.1016/j.diabres.2020.108087 32084455
     [Google Scholar]
  32. HeL. WangJ. PingF. YangN. HuangJ. LiY. XuL. LiW. ZhangH. Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases.JAMA Intern. Med.2022182551351910.1001/jamainternmed.2022.0338 35344001
     [Google Scholar]
  33. WeinsierR.L. WilsonL.J. LeeJ. Medically safe rate of weight loss for the treatment of obesity: A guideline based on risk of gallstone formation.Am. J. Med.199598211511710.1016/S0002‑9343(99)80394‑5 7847427
     [Google Scholar]
  34. Bjerre KnudsenL. MadsenL.W. AndersenS. AlmholtK. de BoerA.S. DruckerD.J. GotfredsenC. EgerodF.L. HegelundA.C. JacobsenH. JacobsenS.D. MosesA.C. MølckA.M. NielsenH.S. NowakJ. SolbergH. ThiT.D.L. ZdravkovicM. MoerchU. Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation.Endocrinology201015141473148610.1210/en.2009‑1272 20203154
     [Google Scholar]
  35. LandoH.M. AlattarM. DuaA.P. Elevated amylase and lipase levels in patients using glucagonlike peptide-1 receptor agonists or dipeptidyl-peptidase-4 inhibitors in the outpatient setting.Endocr. Pract.201218447247710.4158/EP11290.OR 22440997
     [Google Scholar]
  36. WangH. LiuY. TianQ. YangJ. LuR. ZhanS. HaukkaJ. HongT. Incretin‐based therapies and risk of pancreatic cancer in patients with type 2 diabetes: A meta‐analysis of randomized controlled trials.Diabetes Obes. Metab.201820491092010.1111/dom.13177 29193572
     [Google Scholar]
/content/journals/emiddt/10.2174/0118715303283400240521120048
Loading
Efficacy and Safety of Semaglutide in Weight Loss of Non-diabetic People
Endocr Metab Immune Disord Drug Targets 25, 215 (2025); https://doi.org/10.2174/0118715303283400240521120048
/content/journals/emiddt/10.2174/0118715303283400240521120048
/content/journals/emiddt/10.2174/0118715303283400240521120048
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): body mass index; non-diabetic people; Obesity; overweight; semaglutide; weight loss

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test